Valmark Advisers Inc. Buys 2,544 Shares of Pfizer Inc. (NYSE:PFE)

Valmark Advisers Inc. raised its stake in Pfizer Inc. (NYSE:PFE) by 8.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 31,156 shares of the biopharmaceutical company’s stock after acquiring an additional 2,544 shares during the period. Valmark Advisers Inc.’s holdings in Pfizer were worth $1,360,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Advocacy Wealth Management Services LLC increased its holdings in Pfizer by 48.2% in the fourth quarter. Advocacy Wealth Management Services LLC now owns 793 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 258 shares in the last quarter. Winch Advisory Services LLC increased its stake in shares of Pfizer by 69.6% during the 4th quarter. Winch Advisory Services LLC now owns 819 shares of the biopharmaceutical company’s stock worth $36,000 after purchasing an additional 336 shares in the last quarter. Ruggie Capital Group purchased a new position in shares of Pfizer during the 4th quarter worth approximately $44,000. Contravisory Investment Management Inc. grew its stake in Pfizer by 182.6% in the 4th quarter. Contravisory Investment Management Inc. now owns 1,153 shares of the biopharmaceutical company’s stock worth $50,000 after acquiring an additional 745 shares during the period. Finally, Vestor Capital LLC purchased a new stake in Pfizer in the 3rd quarter worth approximately $53,000. Institutional investors own 71.83% of the company’s stock.

In other news, major shareholder Pfizer Inc acquired 50,000 shares of the firm’s stock in a transaction that occurred on Monday, May 13th. The stock was acquired at an average cost of $17.00 per share, with a total value of $850,000.00. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Alexander R. Mackenzie sold 30,000 shares of the company’s stock in a transaction on Thursday, June 20th. The stock was sold at an average price of $44.00, for a total transaction of $1,320,000.00. Following the sale, the insider now directly owns 80,094 shares of the company’s stock, valued at $3,524,136. The disclosure for this sale can be found here. Insiders own 0.09% of the company’s stock.

Several analysts have commented on the stock. Goldman Sachs Group assumed coverage on shares of Pfizer in a research note on Tuesday, May 28th. They issued a “conviction-buy” rating for the company. JPMorgan Chase & Co. reaffirmed a “hold” rating and issued a $46.00 target price on shares of Pfizer in a research note on Monday, June 17th. Credit Suisse Group reissued a “buy” rating and issued a $48.00 target price on shares of Pfizer in a research report on Monday, May 6th. Barclays reissued a “hold” rating and issued a $41.00 target price on shares of Pfizer in a research report on Thursday, May 9th. Finally, Bank of America boosted their target price on shares of Pfizer from $45.00 to $48.00 and gave the stock a “buy” rating in a research report on Monday, April 1st. Thirteen analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $46.22.

PFE stock traded down $0.11 on Friday, hitting $43.32. 37,058,693 shares of the company’s stock traded hands, compared to its average volume of 23,986,496. Pfizer Inc. has a 1-year low of $36.00 and a 1-year high of $46.47. The stock’s fifty day moving average is $42.32. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.27 and a current ratio of 1.54. The firm has a market cap of $239.02 billion, a PE ratio of 14.44, a price-to-earnings-growth ratio of 2.49 and a beta of 0.65.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, April 30th. The biopharmaceutical company reported $0.85 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.75 by $0.10. The business had revenue of $13.12 billion for the quarter, compared to analyst estimates of $13.01 billion. Pfizer had a net margin of 21.31% and a return on equity of 27.48%. The firm’s revenue was up 1.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.77 earnings per share. On average, equities analysts expect that Pfizer Inc. will post 2.88 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, August 2nd will be given a $0.36 dividend. This represents a $1.44 annualized dividend and a yield of 3.32%. Pfizer’s dividend payout ratio is 48.00%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Further Reading: What is a Swap?

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.